Cargando…

Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

Tumor necrosis factor alpha (TNF-α) and interleukin-17 (IL-17) are two pro-inflammatory cytokines involved in the pathophysiology of spondyloarthritis (SpA). Therapies targeting TNF-α or IL-17 are used as a second line among SpA patients failing non-steroidal anti-inflammatory drugs. The choice of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	How Shing Koy, Elsa, Labauge, Pierre, Baillet, Athan, Prati, Clément, Marotte, Hubert, Pers, Yves-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Extra-Articular Manifestations and Comorbidities in Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273400/ https://www.ncbi.nlm.nih.gov/pubmed/34290832 http://dx.doi.org/10.1177/1759720X211025894

Ejemplares similares

Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs
por: Chan, Shirley Chiu Wai, et al.
Publicado: (2021)

Uveitis in spondyloarthritis
por: Rademacher, Judith, et al.
Publicado: (2020)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

Skin manifestations in spondyloarthritis
por: Meier, Katharina, et al.
Publicado: (2020)

Multidisciplinary working in the management of axial and peripheral spondyloarthritis
por: Gudu, Tania, et al.
Publicado: (2020)

Risk of community-acquired pneumonia requiring hospitalization in patients with spondyloarthritis
por: Chung, Ho Yin, et al.
Publicado: (2020)

Mast cells in spondyloarthritis, more than simple inflammatory bystanders?
por: Polivka, Laura, et al.
Publicado: (2020)

Depression in patients with spondyloarthritis: prevalence, incidence, risk factors, mechanisms and management
por: Parkinson, Joel T., et al.
Publicado: (2020)

Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features?
por: Clunie, Gavin, et al.
Publicado: (2020)

Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis
por: Ladehesa-Pineda, María Lourdes, et al.
Publicado: (2020)

The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study
por: Redeker, Imke, et al.
Publicado: (2020)

Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus
por: Fragoulis, George E., et al.
Publicado: (2020)

Psoriatic arthritis and the association with cardiometabolic disease: a narrative review
por: Karmacharya, Paras, et al.
Publicado: (2021)

Increased risk of valvular heart disease in patients with ankylosing spondylitis: a nationwide population-based longitudinal cohort study
por: Siao, Wun-Zhih, et al.
Publicado: (2021)

Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis
por: Lam, Steven H., et al.
Publicado: (2021)

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study
por: van der Horst-Bruinsma, Irene E., et al.
Publicado: (2021)

Subchondral bone attenuation coefficient utility of the sacroiliac margins to differentiate spondyloarthritis and osteitis condensans ilii
por: Terrier, Alexandre, et al.
Publicado: (2022)

Intestinal microbiota changes induced by TNF-inhibitors in IBD-related spondyloarthritis
por: Ditto, Maria Chiara, et al.
Publicado: (2021)

Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study
por: Fakih, Olivier, et al.
Publicado: (2023)

Characterisation of gut microbiota composition in patients with axial spondyloarthritis and its modulation by TNF inhibitor treatment
por: Vallier, Marie, et al.
Publicado: (2023)

Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo
por: Menegatti, Silvia, et al.
Publicado: (2021)

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial
por: Molto, Anna, et al.
Publicado: (2021)

Comorbidity management in spondyloarthritis
por: López-Medina, Clementina, et al.
Publicado: (2020)

Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry
por: Micheroli, Raphael, et al.
Publicado: (2022)

Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort
por: Abawi, Ozair, et al.
Publicado: (2017)

Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry
por: Ciurea, Adrian, et al.
Publicado: (2023)

Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
por: Lindström, Ulf, et al.
Publicado: (2018)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis
por: Derakhshan, Mohammad H, et al.
Publicado: (2020)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Progression From Subclinical Inflammation to Overt Spondyloarthritis in First‐Degree Relatives of Patients in Association With HLA–B27: The Pre‐Spondyloarthritis Cohort
por: de Jong, Henriëtte M. Y., et al.
Publicado: (2022)

Peripheral spondyloarthritis: a neglected entity—state of the art
por: Carron, Philippe, et al.
Publicado: (2020)

The frequency of uveitis in patients with adult versus childhood spondyloarthritis
por: Turk, Matthew, et al.
Publicado: (2020)

Biomechanics in the onset and severity of spondyloarthritis: a force to be reckoned with
por: Iyer, Priyanka, et al.
Publicado: (2023)

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
por: Marona, Jose, et al.
Publicado: (2020)

Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
por: Mease, Philip, et al.
Publicado: (2015)

To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis
por: Perrotta, Fabio Massimo, et al.
Publicado: (2021)

Measuring quality of life of patients with axial spondyloarthritis for economic evaluation
por: Hernandez Alava, Monica, et al.
Publicado: (2022)

Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter
por: Li, Zhixiu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_plani7kjgr33audgsu3vc4c4a2